INKT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Mink Therapeutics Inc (INKT) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available for investment. The stock lacks positive catalysts, has no significant trading signals, and shows weak financial performance. Given the lack of clear upward momentum and no significant news or institutional activity, it's better to hold off on investing in this stock for now.
The technical indicators are neutral to slightly bearish. The MACD is above 0 but contracting, RSI is at 38.026 (neutral zone), and moving averages are converging. The stock closed below the pivot point (11.272) and is approaching the first support level (11.008), indicating potential weakness.
NULL identified. No recent news, no significant insider or hedge fund activity, and no recent congress trading data.
The stock price dropped 4.06% in the regular market and an additional 1.96% in pre-market trading. Financial performance is weak, with no revenue and a negative net income of -$2,887,709, despite some YoY improvement.
In Q3 2025, the company reported no revenue growth (0% YoY) and a net income of -$2,887,709, which improved by 59.84% YoY. EPS increased to -0.65, up 41.30% YoY. Gross margin remains at 0%. Overall, the financials are weak, with no revenue and significant losses.
No data available for analyst ratings or price target changes.
